PubMed21 Apr 2026JAMA● 6/10i Obesity and Cancer: A Translational Science Review.
Shen S, Brown KA, Green AK, Iyengar NM
People with obesity who lost more than 10% of body weight through bariatric procedures or GLP-1 receptor agonists had modest reductions in obesity-associated cancer incidence, with absolute risk reductions of -0.02% to -0.5%. Observational analysis of 30,318 bariatric patients and 1,651,452 GLP-1 users. This provides the first large-scale evidence linking GLP-1-mediated weight loss to cancer risk reduction, potentially expanding the value proposition beyond diabetes and cardiovascular outcomes. The modest effect sizes suggest cancer prevention benefits may require substantial sustained weight loss.
Strategic Signal
GLP-1 cancer prevention data could influence US payer coverage decisions as health systems increasingly focus on total cost of care models. Novo Nordisk and Eli Lilly may leverage this evidence in value-based contracts, given cancer treatment costs averaging $150,000+ per case. However, the modest absolute risk reductions (-0.02% to -0.5%) may limit formulary impact compared to established cardiovascular and kidney benefits that show larger effect sizes.
Original Abstract
IMPORTANCE: Obesity is associated with increased risk of cancer, including endometrial, esophageal, gastric, kidney, colorectal, liver, gallbladder, pancreas, prostate, postmenopausal breast, ovarian, and thyroid cancers. Overweight and obesity account for approximately 10% of new cancer diagnoses annually in the US and up to 50% of certain cancers such as endometrial and hepatobiliary cancer. OBSERVATIONS: Overweight is defined as body mass index (BMI) of 25 to 29.9 and obesity as BMI of 30 or greater. Obesity and overweight are characterized by excess accumulation of adipose tissue, which disrupts its primary function of energy storage. Excess energy, in the form of free fatty acids, is transferred to developing cancer cells and stimulates cancer development through genomic instability caused by oxidative stress and DNA damage. Other defining features of adipose tissue dysfunction include inflammation and altered hormone production such as increased estrogens and leptin and decreased adiponectin. Inflamed adipose tissue is associated with systemic elevations in inflammatory mediators, such as prostaglandin E2, the cytokines interleukin 1β and interleukin 6, and tumor necrosis factor α. These mediators promote tumor growth directly or indirectly by stimulating estrogen biosynthesis, which can promote proliferation of hormone-sensitive cancers such as breast, ovarian, and endometrial cancer, or by suppressing immune-mediated elimination of developing cancer cells through accumulation of myeloid-derived suppressor cells and reductions in the amount and function of cytotoxic T cells and natural killer cells. Inflammation and oxidative stress are also stimulated by obesity-associated depletion of gut commensal bacteria species (eg, Akkermansia muciniphila) and overgrowth of bacterial populations associated with cancer development in preclinical models (eg, Bilophila). In observational studies, patients who lost more than 10% of body weight through bariatric procedures (n = 30 318) or with glucagon-like peptide 1 receptor agonists (n = 1 651 452) had modest reductions in obesity-associated cancer incidence (absolute change, -0.02% to -0.5%). CONCLUSIONS AND RELEVANCE: Overweight and obesity are associated with higher rates of cancer and account for 10% of new cancer diagnoses annually in the US. Weight loss may reduce cancer risk by attenuating adverse effects of obesity, but greater than 10% weight loss may be necessary to reduce cancer risk.